MEDIWOUND LTD (MDWD)
Health Care · Wound care biopharmaceuticals · NASDAQ
MediWound develops enzymatic biotherapies that debride wounds and burns by removing dead tissue, targeting faster healing with biological precision.
What MEDIWOUND LTD does
MediWound Ltd is a biopharmaceutical company specializing in enzymatic wound care products derived from proteolytic enzymes. The company develops and commercializes therapies designed to debride necrotic (dead) tissue from wounds and burns. MediWound's primary focus is on bringing innovative, biologically-derived treatments to the wound care market to accelerate healing and improve patient outcomes.
Themes: ["wound care","enzymatic therapeutics","tissue regeneration","acute care"]
Fundamentals
- Price$14.71 as of 2026-07-09 close
- Market cap$189M as of 2026-07-10
- 1-year return-28.9% as of 2026-07-09 close
- Net margin-180.3% as of 2026-07-10
- Gross margin+19.6% as of 2026-07-10
- ROE-67.2% as of 2026-07-10
- Debt / equity0.20 as of 2026-07-10
- Revenue growth (YoY)-24.6% as of 2026-07-10
- Beta0.14 as of 2026-07-10
Key risks (from latest filing)
["Pre-commercial or early-stage revenue with significant operating losses and negative net margins","Heavy dependence on regulatory approvals and clinical adoption in a competitive wound care market","Substantial revenue decline year-over-year, indicating market traction or product challenges"]
Competitors & peers
- Nuo Therapeutics
- Organogenesis (ORGO)
- Smith & Nephew
- 3M Health Care
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.